orforglipron vs semaglutide Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Head-to-head comparison: Orforglipron vs. Oral

This overall average calorie intake, the paper notes, exceeds expert recommendations for individuals on GLP-1RAs (typically 1,2001,500 kcal/day for females and 1,5001,800 kcal/day for males)

While consensus does not exist regarding the exact synergistic mechanisms by which dual-agonists work, the addition of GIP agonism is posited to improve the HbA1c control and weight loss offered by GLP-1 agonists alone by enhancing insulin secretion, decreasing energy consumption, and stimulating satiety in the hypothalamus

Research published through the National Center for Biotechnology Information details how coordinated activation of GLP-1 and GIP receptors modulates glucose-dependent intracellular signaling, while simultaneous glucagon receptor engagement alters cellular lipid oxidation pathways

These are the only universally recommended steps

Therefore, we proposed to delete HCPCS code C9751 for CY 2026

Faheem N, Sivasubrmanian S